Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 and Uses Thereof
OwnerThomas C. Boone, Jonathan D. Olinerinventors
Life of this patent
Estimating the term…
Abstract
Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
Claims17
An isolated antibody which comprises a heavy chain variable domain having the sequence selected from the group consisting of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, and SEQ ID NO:
- 7;
- wherein said antibody specifically binds to at least one of Ang1 and Ang2 ligands of Tie 2 receptor.
An isolated antibody which comprises a light chain variable domain having the sequence selected from the group consisting of SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, and SEQ ID NO:
- 17;
- wherein said antibody specifically binds to at least one of Ang1 and Ang2 ligands of Tie 2 receptor.
An isolated antibody which comprises a heavy chain variable domain and a light chain variable domain, wherein said heavy chain is comprised of 3 CDRs and said light chain is comprised of 3 CDRs, wherein the sequences of said CDRs of said antibody are selected from the group consisting of:
- (a) SEQ ID NOs:
- 18, 26, 32 of the HC plus SEQ ID NOs:
- 19, 27, 33 of the LC,
- (b) SEQ ID NOs:
- 18, 26, 34 of the HC plus SEQ ID NOs:
- 19, 27, 33 of the LC,
- (c) SEQ ID NOs:
- 18, 26, 35 of the HC plus SEQ ID NOs:
- 20, 27, 36 of the LC,
- (d) SEQ ID NOs:
- 18, 26, 37 of the HC plus SEQ ID NOs:
- 19, 27, 33 of the LC,
- (e) SEQ ID NOs:
- 18, 26, 38 of the HC plus SEQ ID NOs:
- 19, 27, 33 of the LC,
- (f) SEQ ID NOs:
- 18, 26, 35 of the HC plus SEQ ID NOs:
- 19, 27, 33 of the LC,
- (g) SEQ ID NOs:
- 18, 26, 34 of the HC plus SEQ ID NOs:
- 21, 27, 33 of the LC,
- (h) SEQ ID NOs:
- 18, 28, 39 of the HC plus SEQ ID NOs:
- 19, 27, 33 of the LC,
- (i) SEQ ID NOs:
- 18, 26, 34 of the HC plus SEQ ID NOs:
- 22, 27, 33 of the LC,
- (j) SEQ ID NOs:
- 18, 26, 32 of the HC plus SEQ ID NOs:
- 22, 27, 33 of the LC,
- (k) SEQ ID NOs:
- 18, 29, 39 of the HC plus SEQ ID NOs:
- 19, 27, 33 of the LC,
- (l) SEQ ID NOs:
- 18, 26, 34 of the HC plus SEQ ID NOs:
- 23, 27, 33 of the LC,
- (m) SEQ ID NOs:
- 18, 26, 35 of the HC plus SEQ ID NOs:
- 20, 27, 40 of the LC,
- (n) SEQ ID NOs:
- 18, 26, 32 of the HC plus SEQ ID NOs:
- 21, 27, 33 of the LC,
- (o) SEQ ID NOs:
- 18, 26, 35 of the HC plus SEQ ID NOs:
- 24, 27, 33 of the LC,
- (p) SEQ ID NOs:
- 18, 26, 35 of the HC plus SEQ ID NOs:
- 21, 27, 33 of the LC,
- (q) SEQ ID NOs:
- 18, 26, 35 of the HC plus SEQ ID NOs:
- 23, 27, 33 of the LC,
- (r) SEQ ID NOs:
- 18, 26, 34 of the HC plus SEQ ID NOs:
- 20, 30, 33 of the LC,
- (s) SEQ ID NOs:
- 18, 26, 34 of the HC plus SEQ ID NOs:
- 25, 27, 33 of the LC,
- (t) SEQ ID NOs:
- 18, 26, 35 of the HC plus SEQ ID NOs:
- 20, 30, 33 of the LC,
- (u) SEQ ID NOs:
- 18, 26, 34 of the HC plus SEQ ID NOs:
- 20, 27, 40 of the LC, and
- (v) SEQ ID NOs:
- 18, 26, 34 of the HC plus SEQ ID NOs:
- 20, 31, 33 of the LC;
- wherein said antibody specifically binds to at least one of Ang1 and Ang2 ligands of Tie 2 receptor.
A pharmaceutical composition comprising any one of the antibodies selected from the group consisting of H6L7, H5L7, H4L13, H11L7, H10L7, H4L7, H5L6, H2L7, H5L8, H6L8, H3L7, H5L4, H4L12, H6L6, H4L2, H4L6, H4L4, H5L11, H5L1, H4L11, H5L12, and H5L9;
- in admixture with a pharmaceutically acceptable carrier therefor.
A method of inhibiting undesired angiogenesis that comprises administering to a subject in need thereof, an effective amount of any one of the antibodies selected from the group consisting of H6L7, H5L7, H4L13, H11L7, H10L7, H4L7, H5L6, H2L7, H5L8, H6L8, H3L7, H5L4, H4L12, H6L6, H4L2, H4L6, H4L4, H5L11, H5L1, H4L11, H5L12, and H5L9.
Dependencies are inferred from the claim text.